Zevra Therapeutics, Inc. Preferred Stock, Par or Stated Value Per Share
Zevra Therapeutics, Inc. (ZVRA) had Preferred Stock, Par or Stated Value Per Share of $0.00 per share as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockParOrStatedValuePerShare · last filed 2026-08-05
- 2026-06-30: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2026-03-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2025-12-31: Preferred Stock, Par or Stated Value Per Share $0.00.
- 2025-09-30: Preferred Stock, Par or Stated Value Per Share $0.00.
| Period end | Preferred Stock, Par or Stated Value Per Share |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-09 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-07 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-07 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-09 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-10 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-11 |
| 2017-12-31 | $0.00 10-Q · filed 2018-11-09 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-10 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-22 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-30 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-10 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-11 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-13 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-10 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-13 |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-14 |
| 2015-05-31 | $0.00 10-Q · filed 2017-11-09 |
| 2015-04-30 | $0.00 10-K · filed 2018-03-30 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |